Molecule
Clobetasol propionate is a corticosteroid indicated for the treatment of moderate to severe scalp psoriasis in subjects 18 years of age and older, among other approved uses. MedsAcross supplies Clobetasol propionate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Clobetasol Propionate Shampoo, 0.05% is a corticosteroid indicated for the treatment of moderate to severe scalp psoriasis in subjects 18 years of age and older. Limitations of Use: Do not use on the face, axillae or groin. Avoid any contact with the eyes and lips.
Source: US FDA prescribing information
Like other topical corticosteroids, Clobetasol Propionate Shampoo, 0.05%, has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2.
Source: US FDA prescribing information
Clobetasol Propionate Shampoo, 0.05% is for topical use only, and not for ophthalmic, oral or intravaginal use. Clobetasol Propionate Shampoo, 0.05%, should be applied onto dry (not wet) scalp once a day in a thin film to the affected areas only, and left in place for 15 minutes before lathering and rinsing. The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week. Move the hair away from the scalp so that one of the affected areas is exposed. Position the bottle over the lesion. Apply a small amount of the shampoo directly onto the lesion, letting the product naturally flow from the bottle (gently squeeze the bottle), avoiding any contact of the product with the facial skin, eyes or lips. In case of contact, rinse thoroughly with water. Spread the product so that the entire lesion is covered with a thin uniform film.
Source: US FDA prescribing information
None None
Source: US FDA prescribing information
Clobetasol propionate is a highly potent topical corticosteroid that has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis at the lowest doses tested. Cushing’s syndrome, hyperglycemia and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. Systemic absorption may require periodic evaluation for HPA axis suppression. Modify use if HPA axis suppression develops. Children may be more susceptible to systemic toxicity from use of topical corticosteroids. If irritation develops in the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, use of Clobetasol Propionate Shampoo should be discontinued until the infection has been adequately controlled.
Source: US FDA prescribing information
The most common adverse reactions are burning/stinging, pruritus, edema, folliculitis, acne, dry skin, irritant dermatitis, alopecia, urticaria, skin atrophy and telangiectasia.
Source: US FDA prescribing information
Store at USP controlled room temperature 68˚ to 77˚F (20˚ - 25˚C), with excursions permitted between 59˚ and 86˚F (15˚ - 30˚C).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
19 presentations of Clobetasol propionate, sorted by availability.
7 brand names across 1 markets.
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 27 December 1985 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 19 presentations of Clobetasol propionate and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Macleods Pharmaceuticals.
The catalogue lists 7 brand names for Clobetasol propionate, including Byqlovi, Clobetasol Propionate (emollient), Clobetasol Propionate ANDA, clobetasol propionate emollient formulation, Clodan, Impoyz, Tovet (emollient formulation).
Yes. The US FDA first approved Clobetasol propionate on 27 December 1985, according to Drugs@FDA.
At least one listed presentation of Clobetasol propionate must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.